Healthcare Equities

The companies that provide, support or coordinate medical goods and services. This sector spans a broad range of activities – including the development and manufacture of medical equipment, pharmaceuticals and other treatments. Activities range from research to manufacturing, administration, insurance and facilities management. Our Healthcare research includes healthcare services, healthcare information technology (IT), medical devices, biotechnology, biopharmaceuticals and specialty pharmaceuticals.

Synact Pharma (STO: SYNACT) appoints Malin Wikstrand as interim CFO >

Jyoti Prakash, CFA | Healthcare | Comment | 2 days ago

Synact Pharma (STO: SYNACT) appoints Malin Wikstrand as interim CFO >

Jyoti Prakash, CFA | Healthcare | Comment | 2 days ago

SEE ALL COMMENTARY >

Immix Biopharma (IMMX)

Latest price

USD4.60

▾ −0.10 (−2.13)

As at 20/01/2026

Market capitalisation: USD249m

Equities

Equities by Sector

Sectors

Thematics

Latest

Edison explains: Private credit demystified

Edison explains: Finfluencers – #Trending or toxic?

Hansa House View – Q425

Audiovisual

Latest

Tradedoubler – executive interview

From oil to energy solutions: Oando’s strategic vision

Avino Silver and Gold Mines

About Edison

About Edison

Careers

Healthcare Equities

Immix Biopharma (IMMX)

USD4.60

Immix Biopharma — NXC-201's path to BLA submission

Immix Biopharma — Promising NEXICART-2 data; runway extended

Immix Biopharma — Primed to pick up the pace in ALA

See morecontent on

IRLAB Therapeutics (IRLAB-A)

SEK1.90

IRLAB Therapeutics — Next steps laid out for IRL757

IRLAB Therapeutics — Pirepemat stumbles in Phase IIb study

IRLAB Therapeutics — EMA alignment on mesdopetam Phase III plans

See morecontent on

KALA BIO (KALA)

USD0.60

LTR Pharma (LTP)

AUD0.56

LTR Pharma — Sizable upside potential for intranasal delivery

See morecontent on

Medigene (MDG1)

EUR0.13

Making the ordinary, extraordinary: Next generation T cell receptors for precision immunotherapies

Bull, Bear & Beyond – Medigene: executive interview

Medigene – executive interview

See morecontent on

Mendus (IMMU)

SEK5.32

Mendus — ASH 2025 update supports renewed strategy

Mendus — Ovarian cancer: another shot at goal

Mendus — New strategy broadens vididencel potential

See morecontent on

MindMaze Therapeutics (MMTX)

CHF1.20

MindMaze Therapeutics — The next frontier of precision neurotherapeutics

See morecontent on

Newron Pharmaceuticals (NWRN)

CHF23.70

Newron Pharmaceuticals — Phase III ENIGMA-TRS 2 trial underway

Webinar: The CNS renaissance Biotech companies at the forefront

Newron Pharmaceuticals — H125 results reflect evenamide progress

See morecontent on

Nykode Therapeutics (NYKD)

NOK2.47

Nykode Therapeutics — Repositioned to streamline clinical progress

See morecontent on

Ocugen (OCGN)

USD1.67

Ocugen — Novel cell therapies for retinal diseases

See morecontent on

Okyo Pharma (OKYO)

USD2.15

Okyo Pharma — Targeting underserved corneal diseases

See morecontent on

Oncopeptides (ONCO)

SEK3.25

Oncopeptides — Targeted oncology with commercial momentum

See morecontent on

OpGen (OPGN)

—

OpGen — Cash concerns dampen active Q2

OpGen — FIND collaboration advances to development

OpGen — Feasibility milestone from FIND collaboration

See morecontent on

Oryzon Genomics (ORY)

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on